NO964346L - Fremgangsmåte for opplösning av Etodolac ved bruk av glukaminderivater - Google Patents

Fremgangsmåte for opplösning av Etodolac ved bruk av glukaminderivater

Info

Publication number
NO964346L
NO964346L NO964346A NO964346A NO964346L NO 964346 L NO964346 L NO 964346L NO 964346 A NO964346 A NO 964346A NO 964346 A NO964346 A NO 964346A NO 964346 L NO964346 L NO 964346L
Authority
NO
Norway
Prior art keywords
etodolac
pct
glucamine
dissolving
sec
Prior art date
Application number
NO964346A
Other languages
English (en)
Other versions
NO964346D0 (no
Inventor
Brian Michael Adger
Ulrich Conrad Dyer
Martin Woods
John Francis Paul Andrews
Helen Frances Baker
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9407225A external-priority patent/GB9407225D0/en
Priority claimed from GBGB9501455.1A external-priority patent/GB9501455D0/en
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of NO964346D0 publication Critical patent/NO964346D0/no
Publication of NO964346L publication Critical patent/NO964346L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Salter av glukamin eller N-(CMaIkyl)glukamin (formel 1) med S-etodolac, (formel 2) fortrinnsvis med gluminsaltet, er spesielt egnet for rakst innsettende analgetisk virkning. Disse saltene kan fremstilles ved å oppløse racemisk etodolac ved bruk av glukamin eller et N-(CMalkyI)glukamin som oppløsningsmiddel. I tillegg kan vannløselig S-etodolacsalter generelt anvendes ved fremstilling av medikamenter for bruk i hurtig innsettende analgesi og ved kontroll av kronisk smerte, og er spesielt egnet for formuleringer med vedvarende frigjøring.
NO964346A 1994-04-12 1996-10-11 Fremgangsmåte for opplösning av Etodolac ved bruk av glukaminderivater NO964346L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9407225A GB9407225D0 (en) 1994-04-12 1994-04-12 Chiroscience limited
GBGB9501455.1A GB9501455D0 (en) 1995-01-25 1995-01-25 Analgesic agent and its use
PCT/GB1995/000857 WO1995027713A1 (en) 1994-04-12 1995-04-11 Process for the resolution of etodolac using glucamine derivatives

Publications (2)

Publication Number Publication Date
NO964346D0 NO964346D0 (no) 1996-10-11
NO964346L true NO964346L (no) 1996-12-11

Family

ID=26304688

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964346A NO964346L (no) 1994-04-12 1996-10-11 Fremgangsmåte for opplösning av Etodolac ved bruk av glukaminderivater

Country Status (9)

Country Link
US (1) US5811558A (no)
EP (1) EP0755398B1 (no)
JP (1) JPH09511516A (no)
AT (1) ATE221533T1 (no)
AU (1) AU2220695A (no)
DE (1) DE69527617T2 (no)
ES (1) ES2177644T3 (no)
NO (1) NO964346L (no)
WO (1) WO1995027713A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574183A (en) * 1995-01-24 1996-11-12 Albemarle Corporation Preparation of optically active aliphatic carboxylic acids
US6399093B1 (en) 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
GB0007239D0 (en) * 2000-03-24 2000-05-17 Nycomed Imaging As Use
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030232794A1 (en) * 2001-06-26 2003-12-18 Cottam Howard B. Use of STAT-6 inhibitors as therapeutic agents
GB0206505D0 (en) * 2002-03-19 2002-05-01 Euro Celtique Sa Pharmaceutical combination
WO2004026116A2 (en) * 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
ITMI20031471A1 (it) 2003-07-18 2005-01-19 Chemi Spa Processo per la racemizzazione dell'acido etodolico
US7728143B2 (en) 2004-10-08 2010-06-01 Abbott Laboratories Salt and crystalline forms thereof of a drug
SI1868581T1 (sl) * 2005-04-11 2012-06-29 Abbott Lab Farmacevtski sestavki z izboljšanim profilom topnosti za slabo topna zdravila
ITMI20060894A1 (it) 2006-05-05 2007-11-06 Univ Catania Ciclodestrine funzionalizzate con etodolac come agenti di rilascio sito specifico
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
CN102850204B (zh) * 2011-06-29 2015-08-19 徐州医学院 一种(s)-2-芳基丙酸类非甾体抗炎药的拆分方法
WO2013169218A1 (en) 2012-05-08 2013-11-14 Mahmut Bilgic Pharmaceutical compositions of s-etodolac

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501899A (en) * 1983-08-16 1985-02-26 American Home Products Corporation Resolution of (+)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid using cholesteryl aniline
US4520203A (en) * 1983-08-16 1985-05-28 American Home Products Corporation Resolution of (±)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid using cinchonine
US4544757A (en) * 1984-02-16 1985-10-01 American Home Products Corporation Process for the resolution of pyrano[3,4-b]indole-1-acetic acids
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
EP0408496A3 (en) * 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5256293A (en) * 1991-09-20 1993-10-26 Research Corporation Technologies, Inc. Separation of enantiomers of non-steroidal anti-inflammatory drugs and chiral selector therefor

Also Published As

Publication number Publication date
WO1995027713A1 (en) 1995-10-19
EP0755398B1 (en) 2002-07-31
US5811558A (en) 1998-09-22
ES2177644T3 (es) 2002-12-16
ATE221533T1 (de) 2002-08-15
AU2220695A (en) 1995-10-30
DE69527617D1 (de) 2002-09-05
NO964346D0 (no) 1996-10-11
JPH09511516A (ja) 1997-11-18
DE69527617T2 (de) 2003-04-10
EP0755398A1 (en) 1997-01-29

Similar Documents

Publication Publication Date Title
NO964346D0 (no) Fremgangsmåte for opplösning av Etodolac ved bruk av glukaminderivater
MX9302214A (es) Derivados de taxol y proceso para su preparacion
IT1274879B (it) Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
DE69525950D1 (de) Racemisierungsverfahren bei der herstellung von levobupivacaine und analogen
DE69113155D1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3-one-derivate und verfahren zu ihrer herstellung.
GEP20033044B (en) Method for Treating Atherosclerosis
PT99794A (pt) Processo para a preparacao de novas piperazinas 1,4-dissubstituidas
HUT77631A (hu) Eljárás a levobupivakain és származékai rezolválására
ATE207895T1 (de) Thermostabile und lagerfähige kristallmodifikation von n-methyl-n-((1s)-1- phenyl-2-((3s)-3-hydroxypyrrolidin-1-yl)-ethyl) 2,2-diphenyl-acetamid und verfahren zu dessen herstellung
SE9600086D0 (sv) New manufacturing process
FR2702377B1 (fr) Procédé et appareil pour la désinfection d'articles d'habillement, tels que des chaussures.
BR9509176A (pt) Processo de preparação de ácidos 4-metiltio butíricos substituídos alpha racêmicos
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
NO973366L (no) Fremgangsmåte for behandling av multippel sklerose
DE69607113D1 (de) Verfahren zur Racemisierung von optisch aktiven 1-Phenylethylamin-Derivaten
PT793666E (pt) Processo de sililacao
DE69405292D1 (de) 6-Piperazinyl-1H-pyrazolo(3,4-b)pyridin-3-carbonsäuren, ihre Ester, Amide und verwandte Verbindungen, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NO990159L (no) FremgangsmÕte for fremstilling av enantiomerisk anrikede N-acylazetidin-2-karboksylsyrer
BR0008586A (pt) Processo de preparação de aminoácidos quirais e processo de preparação de compostos a partir destes
PL338894A1 (en) Method of increasing optical purity of 2r-[1-hydroxy-1-trifluoromethy-3-cyclopropylopropin-2-yl]-4-chloroaniline
DE69810906D1 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock
AP9801416A0 (en) Method Of treating a plant disease.
ATE210646T1 (de) Verfahren zur herstellung eines beta- aminoalkohols
DK0431305T3 (da) Fremgangsmåde til fremstilling af molluskicide 2,4,5-tribrompyrrol-3-carbonitriler
PT98726A (pt) Processo de transformacao do acido 2-(3-benzoilfenil)propionico-r(-) no isomeros(+)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application